Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 65 and up

Using melatonin to prevent delirium in hospitalized older patients

Official title: Effect of Melatonin Versus Placebo for Prevention of Delirium Among Medically Hospitalized Patients: Study Protocol for a Single-Center, Double-Blinded, Randomised Controlled Trial

Run by Sultan Qaboos University · NCT06509191 · Data updated 2026-11-12

This study is testing if melatonin can help prevent delirium in older patients aged 65 and up who are in the hospital.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages65 Years and up
SexAll
Enrollment240 (estimated)
SponsorSultan Qaboos University
Academic / other
Locations2 sites (Muscat and 1 other locations)
StatusRecruiting
StartedSeptember 30, 2024
Main results expectedMarch 2025
Study endsJune 2025
Registry record updatedJanuary 14, 2025
Trial IDNCT06509191 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients aged 65 years and older who are acutely admitted to the General Internal Medicine Unit.

Probably not a fit

Patients who are already experiencing delirium at the time of randomization or those with specific contraindications will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy of melatonin, a neurohormone that regulates the sleep-wake cycle, in preventing delirium among medically hospitalized patients aged 65 and older. It employs a randomized, double-blind, placebo-controlled design to ensure robust results. Given the high prevalence of delirium in this demographic and its association with adverse health outcomes, the study aims to provide valuable insights into effective prevention strategies. The trial addresses limitations of previous studies by utilizing a larger sample size and a more rigorous methodology.

Why it matters

Potential benefit: If successful, this study could significantly reduce the incidence of delirium in hospitalized older adults, improving their overall health outcomes.

How similar studies have gone: While previous trials have explored melatonin's role in delirium prevention, this study aims to address their limitations, making it a novel approach in this context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient aged 65 years and above acutely admitted under the care of General Internal Medicine Unit

Exclusion Criteria:

* Patients admitted to the ward, however meeting requirement for vasopressors or non-invasive ventilation.
* Patient admitted through emergency to Intensive Care Unit (ICU) or High Dependency Unit (HDU).
* Aphasic patients.
* Patients with language barriers.
* Already taking melatonin or ramelteon at the time of randomization.
* Presence of delirium at the time of randomization.
* If enteral medications are contraindicated due to gastrointestinal conditions.
* If enteral medications are not allowed due to unavailability of nasogastric tube
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (liver function tests) \> 3 times the upper limit of normal.
* Patient on strong cytochrome P450 1A2 (CYP1A2) inhibitors (namely: fluvoxamine and viloxazine) .
* Patient with active alcohol drinking or admitted with alcohol withdrawal syndrome.
* Subject or proxy unable to provide informed consent within 24 hours of admission.
* Patients with the following autoimmune diseases (Rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus).
* Allergy to melatonin.

Where it's running

  • Sultan Qaboos University Hospital
    Muscat, Oman
    Recruiting
  • Sultan Qaboos University Hospital
    Muscat, Oman
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.